Rich Pharmaceuticals (RCHA) CORRESP Correspondence with SEC

Nepia, Inc

January 17, 2012

THE UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Attn: Mrs. Pamela A. Long

Division of Corporation Finance

Mail Stop 7010

100 F. Street NE

Washington, D.C. 20549-7010

Re:  Nepia, Inc  Registration Statement on Form S-1/A File No. 333-173699

Dear Mrs. Long:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nepia, Inc (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1/A to 4:00 PM Eastern Standard Time Eastern Standard Time on January 20, 2012, or as soon thereafter as is practicable.

The Company acknowledges the following:

• Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
• The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
• The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Thank you for your assistance. Please call with any questions.

Nepia, Inc

By:

/s/ Li Deng Ke

Li Deng Ke

Chief Executive Officer

Tian Bei W. Rd. Yung Guang Tian Di Ming Xing

Ge, Unit 1503, Shenzhen, China